Joo‐Hee Yi

1.2k total citations
11 papers, 919 citations indexed

About

Joo‐Hee Yi is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Joo‐Hee Yi has authored 11 papers receiving a total of 919 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Radiology, Nuclear Medicine and Imaging and 2 papers in Molecular Biology. Recurrent topics in Joo‐Hee Yi's work include HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Peptidase Inhibition and Analysis (4 papers). Joo‐Hee Yi is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Peptidase Inhibition and Analysis (4 papers). Joo‐Hee Yi collaborates with scholars based in United States, Switzerland and France. Joo‐Hee Yi's co-authors include Sandhya Girish, Howard A. Burris, Shanu Modi, Muralidhar Beeram, Ian E. Krop, Suzanne F. Jones, Scott N. Holden, Mark X. Sliwkowski, Stuart Lutzker and Jay Tibbitts and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Pharmacology & Therapeutics.

In The Last Decade

Joo‐Hee Yi

11 papers receiving 889 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joo‐Hee Yi United States 9 600 525 256 97 85 11 919
Yu-Waye Chu United States 5 992 1.7× 738 1.4× 204 0.8× 85 0.9× 34 0.4× 5 1.2k
Janneke D.M. Molkenboer‐Kuenen Netherlands 16 414 0.7× 535 1.0× 211 0.8× 98 1.0× 48 0.6× 33 956
Peter Ruf Germany 15 609 1.0× 513 1.0× 323 1.3× 369 3.8× 32 0.4× 30 998
Anton G.T. Terwisscha van Scheltinga Netherlands 19 460 0.8× 507 1.0× 293 1.1× 67 0.7× 46 0.5× 30 1.0k
Lisa M. Garrett United States 3 503 0.8× 427 0.8× 354 1.4× 65 0.7× 32 0.4× 3 833
Zohreh Varasteh Sweden 21 610 1.0× 727 1.4× 310 1.2× 88 0.9× 36 0.4× 42 1.2k
Nadège Gaborit France 18 449 0.7× 264 0.5× 370 1.4× 68 0.7× 18 0.2× 24 773
Kathrin Schwager Switzerland 14 482 0.8× 487 0.9× 301 1.2× 375 3.9× 22 0.3× 17 1.0k
Olga Ab United States 11 577 1.0× 398 0.8× 190 0.7× 73 0.8× 17 0.2× 23 776
David Egging Netherlands 14 312 0.5× 322 0.6× 234 0.9× 85 0.9× 19 0.2× 22 723

Countries citing papers authored by Joo‐Hee Yi

Since Specialization
Citations

This map shows the geographic impact of Joo‐Hee Yi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joo‐Hee Yi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joo‐Hee Yi more than expected).

Fields of papers citing papers by Joo‐Hee Yi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joo‐Hee Yi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joo‐Hee Yi. The network helps show where Joo‐Hee Yi may publish in the future.

Co-authorship network of co-authors of Joo‐Hee Yi

This figure shows the co-authorship network connecting the top 25 collaborators of Joo‐Hee Yi. A scholar is included among the top collaborators of Joo‐Hee Yi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joo‐Hee Yi. Joo‐Hee Yi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Li, Chunze, Priya Agarwal, Susan Dent, et al.. (2015). Abstract P4-15-09: Phase 1 study of trastuzumab emtansine in HER2-positive metastatic breast cancer patients with normal or reduced hepatic function. Cancer Research. 75(9_Supplement). P4–15. 1 indexed citations
2.
Dere, Randall, Joo‐Hee Yi, Ola M. Saad, et al.. (2013). PK Assays for Antibody–Drug Conjugates: Case Study with Ado-Trastuzumab Emtansine. Bioanalysis. 5(9). 1025–1040. 50 indexed citations
3.
4.
Gupta, Manish, Bei Wang, Timothy J. Carrothers, et al.. (2013). Effects of Trastuzumab Emtansine (T‐DM1) on QT Interval and Safety of Pertuzumab Plus T‐DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer. Clinical Pharmacology in Drug Development. 2(1). 11–24. 32 indexed citations
5.
Carrasco‐Triguero, Montserrat, Joo‐Hee Yi, Randall Dere, et al.. (2013). Immunogenicity Assays for Antibody–Drug Conjugates: Case Study with Ado-Trastuzumab Emtansine. Bioanalysis. 5(9). 1007–1023. 38 indexed citations
6.
Lu, Dan, Howard A. Burris, Bei Wang, et al.. (2012). Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. Current Drug Metabolism. 13(7). 911–922. 30 indexed citations
7.
Carrasco‐Triguero, Montserrat, et al.. (2012). Overcoming Soluble Target Interference in An Anti-Therapeutic Antibody Screening Assay For An Antibody–Drug Conjugate Therapeutic. Bioanalysis. 4(16). 2013–2026. 26 indexed citations
8.
9.
Krop, Ian E., Muralidhar Beeram, Shanu Modi, et al.. (2010). Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer. Journal of Clinical Oncology. 28(16). 2698–2704. 437 indexed citations
10.
LoRusso, Patricia, Sandhya Girish, Howard A. Burris, et al.. (2009). Population Pharmacokinetics of Trastuzumab-DM1, a First-in-Class HER2 Antibody-Drug Conjugate Given Every 3 Weeks (q3w) and Weekly (qw) to Patients with HER2-Positive Metastatic Breast Cancer (MBC).. Cancer Research. 69(24_Supplement). 5099–5099. 3 indexed citations
11.
Combs, Daniel L., Timothy D. Henry, John J. López, et al.. (2002). A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clinical Pharmacology & Therapeutics. 72(1). 20–32. 213 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yu-Waye Chu Breakdown of academic impact, for papers by Janneke D.M. Molkenboer‐Kuenen Breakdown of academic impact, for papers by Peter Ruf Breakdown of academic impact, for papers by Anton G.T. Terwisscha van Scheltinga Breakdown of academic impact, for papers by Lisa M. Garrett Breakdown of academic impact, for papers by Zohreh Varasteh Breakdown of academic impact, for papers by Nadège Gaborit Breakdown of academic impact, for papers by Kathrin Schwager Breakdown of academic impact, for papers by Olga Ab Breakdown of academic impact, for papers by David Egging
Rankless by CCL
2026